$COO Added as New Pick Amid Strategic Review at 14.5x Forward
ACCE adds $COO as a new pick. CooperCompanies trades at 14.5x forward earnings, posted record Q2 FY2026 revenue of $1.08B, and its board has opened a formal strategic review.
ACCE has added COO (The Cooper Companies) to its picks list. The alert flags a medical-device business trading at 14.5x forward earnings, roughly 26% below its 52-week high, while its board runs a formal strategic review — a process that could materially change the company's structure or ownership.
CooperCompanies reported record revenue of $1.08B in Q2 FY2026, up 7.9% year over year. Year-over-year earnings growth came in at 26.9%. The company also edged past consensus estimates, delivering a beat of 0.1% on its most recent quarter — its tenth consecutive earnings beat according to the alert headline.
At $67.88 as of June 12, 2026, the stock carries a market cap of $13.24B. The trailing P/E sits at 57.5, which reflects historical earnings drag, but the forward P/E of 14.5x is where the valuation argument lives. Analyst consensus targets $80.57, implying roughly 19% upside from the current price.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
What it means
The ACCE score for COO is 48 out of 100 — a middling composite. Breaking that down: Growth scores 56, Value 53, Quality 50, and Momentum 31. The weak Momentum score is consistent with the 1-year return of -4.2% and the stock sitting well off its highs. This is not a stock the market is chasing right now.
Quality metrics are modest but positive. Return on equity is 2.9%, net margin is 5.6%, and FCF yield is 3.3%. Earnings quality is flagged as strong, which matters when evaluating whether reported profits translate into real cash generation.
One number worth flagging: ACCE's 6-model fair value estimate sits at $53.37, which is 21.4% below the current price of $67.88. That gap between the quantitative fair-value model and the analyst consensus target of $80.57 reflects genuine disagreement about what COO is worth. The strategic review is the variable neither model can fully price — a sale, spin-off, or restructuring could shift the calculus quickly in either direction.
The pick thesis rests on a combination of factors: a consistent earnings track record, a forward multiple that looks reasonable relative to the company's growth rate, and a board-level process that introduces event-driven upside. The risks are real too. Momentum is weak, the 6-model fair value suggests the stock may not be cheap on fundamentals alone, and strategic reviews can drag on or conclude without a transaction.
This is a developing story. The outcome of the strategic review is unknown, and COO's price will likely respond sharply to any announcement. Follow updates at acceinvestments.com/stocks/COO.
See the full picture, free
ACCE scores thousands of stocks across six valuation models, with fair value, conviction and the full thesis on every name. Start free, no card required.
